Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617091 | 0.95 | KDM4E (0.73) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL9784423 | 0.89 | KDM4E (0.68) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL6127192 | 0.86 | KDM4E (0.89) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL5246151 | 0.83 | KDM4E (0.78) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL6928579 | 0.82 | KDM4E (0.76) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL4045277 | 0.81 | KDM4E (0.81) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL18197872 | 0.80 | KDM4E (0.84) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL18906066 | 0.80 | KDM4E (0.83) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL14996215 | 0.79 | KDM4E (0.71) | KDM4EGAATSHRNPC1CYP1A2 | |
| SCHEMBL1935628 | 0.79 | GAA (1.00) | KDM4EGAATSHRNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | KDM4E 1058/4885GAA 131/4885TSHR 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.